The top panel shows the proportion of patients who received one of the six treatments as first-line therapy among all patients with prostate cancer during the years 2014 through mid-2016 in each region. The bottom left panel shows the difference of proportions between oral drug (abiraterone or enzalutamide) and docetaxel for first-line treatment among all patients with prostate cancer during the years 2014 through mid-2016 in each region. The darker blue indicates more prescriptions for an oral therapy than docetaxel. The bottom right panel shows the difference of proportion between abiraterone and enzalutamide for first-line treatment among all patients with prostate cancer during the years 2014 through mid-2016 in each region. The darker green indicates more prescriptions for abiraterone than enzalutamide. Patients with prostate cancer were defined as patients with at least one diagnostic code as a medical claim during the years 2014 and mid-2016. Methods to generate this figure are in Supplementary Materials, Section 6.1.
Abbreviations: New England (NE): Connecticut (CT), Maine (ME), Massachusetts (MA), New Hampshire (NH), Rhode Island (RI), Vermont (VT), Middle Atlantic (MA): New Jersey (NJ), New York (NY), Pennsylvania (PA), East North Central (ENC): Illinois (IL), Indiana (IN), Michigan (MI), Ohio (OH), Wisconsin (WI), West North Central (WNC): Iowa (IA), Kansas (KS), Minnesota (MN), Missouri (MO), Nebraska (NE), North Dakota (ND), South Dakota (SD), South Atlantic (SA): Delaware (DE), Washington D.C. (DC), Florida (FL), Georgia (GA), Maryland (MD), North Carolina (NC), South Carolina (SC), Virginia (VA), West Virginia (WV), East South Central (ESC): Alabama (AL), Kentucky (KY), Mississippi (MS), Tennessee (TN), West South Central (WSC): Arkansas (AR), Louisiana (LA), Oklahoma (OK), and Texas (TX), Mountain (M): Arizona (AZ), Colorado (CO), Idaho (ID), Montana (MT), Nevada (NV), New Mexico (NM), Utah (UT), Wyoming (WY), Pacific (PAC): Alaska (AK), California (CA), Hawaii (HI), Oregon (OR), Washington (WA)